Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC

Completed · Phase 2

Conditions studied: Stage III Non-small Cell Lung Cancer, Unresectable

In brief

The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.

Key facts

Study ID
NCT03822351
Run by
MedImmune LLC
People needed
189
Starts
2018-12-19
Expected to finish
2023-07-18
Last updated by the study team
2024-10-08

Who can join

Age: 18 and older, up to 99. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.